Nwamaka Ngumezi
Psychiatric/Mental Health · Dallas, TXNPI 1114495983
Payments from drug & device makers
Across 227 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$755
- AbbVie$707
- Alkermes, Inc.$451
- Otsuka America Pharmaceutical, Inc.$450
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$371
- Johnson & Johnson$235
- plus $1K from 18 others
What the payments were for
- Food & beverage$4,103100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $755 |
| AbbVie | 67 | $707 |
| Alkermes, Inc. | 21 | $451 |
| Otsuka America Pharmaceutical, Inc. | 22 | $450 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $371 |
| Johnson & Johnson | 11 | $235 |
| Corium, LLC | 5 | $150 |
| Sunovion Pharmaceuticals Inc. | 8 | $131 |
| Almatica Pharma LLC | 4 | $98 |
| Lundbeck LLC | 5 | $97 |
| Bausch Health US, LLC | 4 | $82 |
| Noven Therapeutics, LLC | 4 | $75 |
| Axsome Therapeutics, Inc. | 4 | $75 |
| Tris Pharma Inc | 3 | $66 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Neurocrine Biosciences, Inc. | 2 | $52 |
| Merck | 3 | $50 |
| Jazz Pharmaceuticals Inc. | 2 | $46 |
| Ironshore Pharmaceuticals Inc. | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Validus Pharmaceuticals LLC | 1 | $32 |
| Neos Therapeutics, LP | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Eisai Inc. | 1 | $11 |
How this compares
$4,103 in reported general payments places this provider in the 85th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 42 | $966 |
| Escitalopram Oxalate | 33 | $691 |
| Doxepin Hcl | 19 | $651 |
| Ziprasidone Hcl | 14 | $633 |
| Clonazepam | 50 | $558 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $539 |
| Buspirone Hcl | 38 | $497 |
| Duloxetine Hcl | 26 | $416 |
| Trazodone Hcl | 27 | $332 |
| Aripiprazole | 30 | $328 |
| Alprazolam | 97 | $256 |
| Zolpidem Tartrate | 31 | $253 |
| Lamotrigine | 35 | $251 |
| Bupropion Hcl SrBupropion Hcl | 24 | $250 |
| Oxcarbazepine | 11 | $163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $98 | $14729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Dallas
- Kimberly ThompsonDallas$25K
- Melissa RiveraDallas$19K
- Jillian AdamsDallas$13K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.